Skip to content

Author

A. D. de Vries

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Development and external validation of a clinical prediction model to estimate unfavorable graft outcome in patients with severe kidney transplant rejection eligible for treatment with alemtuzumab.

INTRODUCTION Alemtuzumab is an effective therapy for severe kidney transplant rejection. Yet, not all patients benefit from this treatment, while they are at risk for its toxic effects. A prediction model could help to identify these patients and potentially guide treatment decisions. METHODS We developed a predictio...

Lukas K. van Vugt, D. J. van den Broek, Pedro Miranda Afonso et al. · 0 citations
Sep 2026

Plasma versus Whole Blood Tacrolimus Concentration and Outcomes After Kidney Transplantation: Post Hoc Analysis of the ALLEGRO Trial.

BACKGROUND Tacrolimus is the cornerstone of immunosuppressive treatment after kidney transplantation. Its application requires therapeutic drug monitoring, which is routinely performed by assessment of whole blood tacrolimus concentrations (WBTC) that largely comprises a pharmacologically inactive fraction. Monitoring...

J. Jonker, J. C. van den Born, D. Kremer et al. · 0 citations
Sep 2026

Chimeric HLA Antibody Receptor (CHAR) T Cells to Specifically Eliminate HLA-DQ-Specific B Cells.

BACKGROUND CAR T cell therapy has revolutionized the treatment of hematological malignancies by effectively eliminating tumor cells. In the field of kidney transplantation, comparable cellular therapies are being explored to facilitate transplantation and prevent graft rejection. Chimeric HLA antibody receptor (CHAR) T...

Carolt Arana, I. Gille, R. Hagedoorn et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.